Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study found that repeated finasteride administration in male Wistar rats led to increased depression-like behavior, suggesting an animal model for investigating finasteride's neuropsychiatric effects is viable.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This article reviews the challenges in diagnosing mild hyperandrogenism in adolescent girls, discussing potential causes like PCOS and treatment options, but reports no new clinical results.

This study suggests that androstendione and DHEA are useful indicators for diagnosing hyperandrogenemia in hirsute women, while DHEAS was not found to be helpful.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

Finasteride helped treat a 28-year-old's facial skin condition.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

Dutasteride reduces DHT more effectively than finasteride.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This review discusses dermatologic signs in childhood endocrine disorders and highlights their importance in early diagnosis and treatment, but it reports no new clinical findings.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This article reviews the differential diagnosis of mild hyperandrogenism in adolescent girls, discussing potential causes such as PCOS and nonclassic adrenal hyperplasia, but presents no new data.

This study observed that finasteride, especially when combined with electrolysis, effectively reduced hair growth in women with hirsutism over six months.

Blood AMH levels are higher in women with PCOS than in those with other similar conditions.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This review discusses the role of extracellular vesicles from specific skin cells in wound healing, emphasizing their potential in regenerative medicine and reporting no new experimental results.